Publication: Use of Xylazine in Drug-Facilitated Crimes
Submitted Date
Received Date
Accepted Date
Issued Date
2018-07-01
Copyright Date
Announcement No.
Application No.
Patent No.
Valid Date
Resource Type
Edition
Resource Version
Language
File Type
No. of Pages/File Size
ISBN
ISSN
15564029
00221198
00221198
eISSN
Scopus ID
WOS ID
Pubmed ID
arXiv ID
Call No.
Other identifier(s)
2-s2.0-85032955356
Journal Title
Volume
Issue
item.page.oaire.edition
Start Page
End Page
Access Rights
Access Status
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Physical Location
Bibliographic Citation
Journal of Forensic Sciences. Vol.63, No.4 (2018), 1325-1330
Citation
Jatupon Krongvorakul, Saranya Auparakkitanon, Satariya Trakulsrichai, Pitsucha Sanguanwit, Jetjamnong Sueajai, Nantida Noumjad, Winai Wananukul (2018). Use of Xylazine in Drug-Facilitated Crimes. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/45109.
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Use of Xylazine in Drug-Facilitated Crimes
Alternative Title(s)
Author's Affiliation
Author's E-mail
Editor(s)
Editor's Affiliation
Corresponding Author(s)
Creator(s)
Compiler
Advisor(s)
Illustrator(s)
Applicant(s)
Inventor(s)
Issuer
Assignee
Other Contributor(s)
Series
Has Part
Abstract
© 2017 American Academy of Forensic Sciences Human xylazine poisoning is uncommon. This report describes the use of xylazine for intentional poisoning with criminal intent. Two incidents occurred within 3 weeks: the first involved one victim, and the second involved two victims. The clinical presentations were brief coma, bradycardia, hypotension, and hyperglycemia. The victims recalled having been given a drink from a stranger in a hospital waiting room before loss of consciousness. In the first case, general drug screening by gas chromatography/mass spectrometry (MS) revealed xylazine in the gastric contents, but liquid chromatography–tandem MS (LC-MS/MS) of serum did not. In the second incident, LC-MS/MS screening of both victims’ urine and serum samples revealed an unknown peak in the total ion chromatograms, which a molecular mass database identified as morantel or xylazine. The latter was confirmed by comparison with a xylazine standard. Based on this report, we suggest that xylazine should be classified as a controlled drug.